Sorry!! The article you are trying to read is not available now.
Last Price  /  Updated: 8:10 PM EST, Feb 21, 2014  /  Add to My Watchlist      
(PATH) Community Analysis from
April 18, 2014
Courtesy of Benzinga. NuPathe Inc. (NASDAQ: PATH), today announced that it has granted time-based stock options to Armando Anido,...(read more)
(Benzinga, 8/31/11)
NuPathe announced on Tuesday that its application for FDA approval of its migraine patch Zelrix has been rejected, as the agency cited safety and manufacturing issues as the primary reasons for...(read more)
(Benzinga, 10/19/10)
Shares of specialty pharmaceutical company NuPathe (NASDAQ:PATH) have climbed 16.28% to $7.00 on the back of promising top-line safety results for its migraine drug Zelrix. A total of 183 patients were enrolled in the trial, and Zelrix...(read more)
NuPathe (PATH) Company Overview

There is no analysis for PATH yet. But you can go to Wikinvest to help create one!

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here